# US 2023/0054860 A1 · Tap63 regulated oncogenic long non-coding rnas

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0054860 A1
- Document ID: US20230054860A1
- Status: Published application
- Kind: A1
- Application number: 17/791,706
- Filed: 2021-01-13
- Published: 2023-02-23
- Earliest claimed: 2020-01-13
- Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc.
- Applicants: H. Lee Moffitt Cancer Center and Research Institute, Inc.
- Inventors: Elsa R. FLORES; Marco NAPOLI
- Web page: https://patentgrep.com/patent/US20230054860A1

## CPC

- G01N 33/5011: {for testing antineoplastic activity}
- C12Q 1/686: Polymerase chain reaction [PCR]
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/5308: {for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites}
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/178: miRNA, siRNA or ncRNA
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Disclosed herein are 2 novel long non-coding RNAs (lncRNAs), TROLL-2 and TROLL-3. It is shown herein that lncRNAs TROLL-2 and TROLL-3, as well as their effector WDR26, are suitable targets for cancer therapies and can be used to make prognostic determinations about a cancer and determine if immune checkpoint inhibitors should be used to treat a cancer.

## Claims

### Claim 1

A method of assessing tumor grade and/or progression of a cancer and/or metastasis or detecting the presence of a cancer in a subject comprising obtaining a tissue sample from a subject and measuring the expression level of the long non-coding RNA for TROLL-1, TROLL-2, TROLL-3, TROLL-5, TROLL-7, and/or TROLL-8 and/or expression level of WDR26; wherein the higher the level of lncRNA for TROLL-1, TROLL-2, TROLL-3, TROLL-5, TROLL-7, and/or TROLL-8 and/or the higher the level of WDR26 and/or NCOA5 and/or the more WDR26 and/or NCOA5 localized in the cytoplasm of a cell relative to a control, the greater the severity and/or invasiveness of the tumor is indicated; or wherein the presence of lncRNA for TROLL-1, TROLL-2, TROLL-3, TROLL-5, TROLL-7, and/or TROLL-8 indicates the presence of a cancer in the tissue sample from the subject.

### Claim 2

A method of assessing the efficacy of a cancer treatment regimen administered to a subject comprising obtaining a tissue sample from a subject and measuring the expression level of the long non-coding RNA for TROLL-1, TROLL-2, TROLL-3, TROLL-5, TROLL-7, and/or TROLL-8; and/or measuring the expression level of WDR26 and/or NCOA5; and/or measuring the intracellular localization of WDR26 and/or NCOA5 relative to a control; wherein when the expression level of lncRNA for TROLL-1, TROLL-2, TROLL-3, TROLL-5, TROLL-7, and/or TROLL-8 and/or the expression level of WDR26 and/or NCOA5 is i) higher than a negative control, ii) equivalent to or has not decreased relative to a positive control, and/or iii) wherein the cytoplasmic localization of WDR26 and/or NCOA5 is greater than a negative control and/or equivalent to or has not decreased relative to a positive control indicates that the treatment regimen is not efficacious; preferably wherein the positive control is a reference gene or pretreatment sample from the subject whose cancer treatment regimen is being assessed.

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6

A method of treating a cancer in a subject comprising obtaining a tissue sample from a subject receiving a cancer treatment regimen and measuring the expression level of the long non-coding RNA for TROLL-1, TROLL-2, TROLL-3, TROLL-5, TROLL-7, and/or TROLL-8; and/or measuring the expression level of WDR26 and/or NCOA5; and/or measuring the intracellular localization of WDR26 and/or NCOA5 relative to a control; wherein when the expression level of lncRNA for TROLL-1, TROLL-2, TROLL-3, TROLL-5, TROLL-7, and/or TROLL-8 and/or the expression level of WDR26 and/or NCOA5 is i) higher than a negative control, ii) equivalent to or has not decreased relative to a positive control, and/or iii) wherein the cytoplasmic localization of WDR26 and/or NCOA5 is greater than a negative control and/or equivalent to or has not decreased relative to a positive control; indicates that the treatment regimen is not efficacious; and wherein the method further comprises changing the treatment regimen when the treatment regimen is not efficacious.

### Claim 7

A method of treating a cancer in a subject comprising i) obtaining a tissue sample from the subject; ii) assaying the tissue sample for the presence and/or expression level of the long non-coding RNA for TROLL-1, TROLL-2, TROLL-3, TROLL-5, TROLL-7, and/or TROLL-8; wherein the presence of lncRNA for TROLL-1, TROLL-2, TROLL-3, TROLL-5, TROLL-7, and/or TROLL-8 indicates the presence of a cancer in the tissue sample from the subject; and iii) administering to a subject positive for TROLL-1, TROLL-2, TROLL-3, TROLL-5, TROLL-7, and/or TROLL-8 an anti-cancer agent and/or immunotherapy.

### Claim 8

A method of screening for a potential anti-cancer agent comprising contacting a cancer cell with the anti-cancer agent and measuring expression levels of TROLL-1, TROLL-2, TROLL-3, TROLL-5, TROLL-7, and/or TROLL-8; wherein decreased expression of TROLL-1, TROLL-2, TROLL-3, TROLL-5, TROLL-7, and/or TROLL-8 indicates that the potential anti-cancer agent reduces cancer or measuring expression levels of WDR26 and/or NCOA5 wherein decreased expression of WDR26 and/or NCOA5 indicates that the potential anti-cancer agent reduces cancer.

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The method of claim 1, wherein the level of long non-coding RNA for TROLL-1, TROLL-2, TROLL-3, TROLL-5, TROLL-7, and/or TROLL-8 and/or expression level of WDR26 and/or NCOA5 is measured by in situ hybridization, PCR, quantitative RCR, real-time PCR, quantitative, real-time PCR, reverse transcriptase PCR, Western blot, northern blot, and/or microarray; preferably wherein the level of long non-coding RNA from TROLL-1, TROLL-2, TROLL-3, TROLL-5, TROLL-7, and/or TROLL-8 and/or expression level of WDR26 and/or NCOA5 is measured by PCR, quantitative RCR, real-time PCR, quantitative, real-time PCR, reverse transcriptase PCR and wherein the primers used in the PCR reaction or the primers of Table 3 or Table 5.

### Claim 11

(canceled)

### Claim 12 (depends on 1)

The method of claim 1, wherein the cancer comprises a TAP63 regulated cancer; preferably wherein the cancer comprises breast cancer, liver cancer, lung cancer, ovarian, colon, or melanoma; most preferably wherein the cancer comprises triple negative breast cancer.

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15

A kit for the detection, diagnosis, and/or prognosis of a cancer comprising any of the primers of Table 3 and/or Table 5.

### Claim 16 (depends on 2)

The method of claim 2, wherein the level of long non-coding RNA for TROLL-1, TROLL-2, TROLL-3, TROLL-5, TROLL-7, and/or TROLL-8 and/or expression level of WDR26 and/or NCOA5 is measured by in situ hybridization, PCR, quantitative RCR, real-time PCR, quantitative, real-time PCR, reverse transcriptase PCR, Western blot, northern blot, and/or microarray; preferably wherein the level of long non-coding RNA from TROLL-1, TROLL-2, TROLL-3, TROLL-5, TROLL-7, and/or TROLL-8 and/or expression level of WDR26 and/or NCOA5 is measured by PCR, quantitative RCR, real-time PCR, quantitative, real-time PCR, reverse transcriptase PCR and wherein the primers used in the PCR reaction or the primers of Table 3 or Table 5.

### Claim 17 (depends on 2)

The method of claim 2, wherein the cancer comprises a TAP63 regulated cancer; preferably wherein the cancer comprises breast cancer, liver cancer, lung cancer, ovarian, colon, or melanoma; most preferably wherein the cancer comprises triple negative breast cancer.

### Claim 18 (depends on 6)

The method of claim 6, wherein the level of long non-coding RNA for TROLL-1, TROLL-2, TROLL-3, TROLL-5, TROLL-7, and/or TROLL-8 and/or expression level of WDR26 and/or NCOA5 is measured by in situ hybridization, PCR, quantitative RCR, real-time PCR, quantitative, real-time PCR, reverse transcriptase PCR, Western blot, northern blot, and/or microarray; preferably wherein the level of long non-coding RNA from TROLL-1, TROLL-2, TROLL-3, TROLL-5, TROLL-7, and/or TROLL-8 and/or expression level of WDR26 and/or NCOA5 is measured by PCR, quantitative RCR, real-time PCR, quantitative, real-time PCR, reverse transcriptase PCR and wherein the primers used in the PCR reaction or the primers of Table 3 or Table 5.

### Claim 19 (depends on 6)

The method of claim 6, wherein the cancer comprises a TAP63 regulated cancer; preferably wherein the cancer comprises breast cancer, liver cancer, lung cancer, ovarian, colon, or melanoma; most preferably wherein the cancer comprises triple negative breast cancer.

### Claim 20 (depends on 7)

The method of claim 7, wherein the level of long non-coding RNA for TROLL-1, TROLL-2, TROLL-3, TROLL-5, TROLL-7, and/or TROLL-8 and/or expression level of WDR26 and/or NCOA5 is measured by in situ hybridization, PCR, quantitative RCR, real-time PCR, quantitative, real-time PCR, reverse transcriptase PCR, Western blot, northern blot, and/or microarray; preferably wherein the level of long non-coding RNA from TROLL-1, TROLL-2, TROLL-3, TROLL-5, TROLL-7, and/or TROLL-8 and/or expression level of WDR26 and/or NCOA5 is measured by PCR, quantitative RCR, real-time PCR, quantitative, real-time PCR, reverse transcriptase PCR and wherein the primers used in the PCR reaction or the primers of Table 3 or Table 5.

### Claim 21 (depends on 7)

The method of claim 7, wherein the cancer comprises a TAP63 regulated cancer; preferably wherein the cancer comprises breast cancer, liver cancer, lung cancer, ovarian, colon, or melanoma; most preferably wherein the cancer comprises triple negative breast cancer.

### Claim 22 (depends on 8)

The method of claim 8, wherein the level of long non-coding RNA for TROLL-1, TROLL-2, TROLL-3, TROLL-5, TROLL-7, and/or TROLL-8 and/or expression level of WDR26 and/or NCOA5 is measured by in situ hybridization, PCR, quantitative RCR, real-time PCR, quantitative, real-time PCR, reverse transcriptase PCR, Western blot, northern blot, and/or microarray; preferably wherein the level of long non-coding RNA from TROLL-1, TROLL-2, TROLL-3, TROLL-5, TROLL-7, and/or TROLL-8 and/or expression level of WDR26 and/or NCOA5 is measured by PCR, quantitative RCR, real-time PCR, quantitative, real-time PCR, reverse transcriptase PCR and wherein the primers used in the PCR reaction or the primers of Table 3 or Table 5.

### Claim 23 (depends on 8)

The method of claim 8, wherein the cancer comprises a TAP63 regulated cancer; preferably wherein the cancer comprises breast cancer, liver cancer, lung cancer, ovarian, colon, or melanoma; most preferably wherein the cancer comprises triple negative breast cancer.
